SOPHiA GENETICS
SOPH
34 hedge funds and large institutions have $54.7M invested in SOPHiA GENETICS in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 5 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
0% more funds holding
Funds holding: 34 → 34 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1.29% less ownership
Funds ownership: 33.77% → 32.48% (-1.3%)
22% less capital invested
Capital invested by funds: $70.4M → $54.7M (-$15.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.45M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$1.32M |
| 3 |
Millennium Management
New York
|
+$794K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$204K |
| 5 |
PVI
Pura Vida Investments
New York
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.45M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.11M |
| 3 |
Barclays
London,
United Kingdom
|
-$209K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$91.9K |
| 5 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
-$59.6K |
SOPH Hedge Fund Activity: Q3 2022 in Review
34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in SOPHiA GENETICS (SOPH) for Q3 2022, worth a combined $54.7M — down 22% from $70.4M a quarter earlier.
Fund positioning in SOPH was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.45M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.45M.
- 34 institutional investors held SOPHiA GENETICS (SOPH) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $54.7M of SOPHiA GENETICS stock for Q3 2022, down 22% quarter-over-quarter.
- 5 funds opened new SOPHiA GENETICS positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest SOPHiA GENETICS buyer in Q3 2022 was Morgan Stanley, an estimated $1.45M added.
- The largest SOPHiA GENETICS seller in Q3 2022 was T. Rowe Price Associates, an estimated $3.45M sold.
Based on aggregated 13F filings for Q3 2022.